Azenta (AZTA) Q3 EPS Jumps 36%
Azenta (NASDAQ:AZTA), a provider of life sciences solutions focusing on sample management and genomics services, released its third-quarter fiscal 2025 results on August 5, 2025. The headline: Non-GAAP profitability beat expectations, but GAAP revenue was flat and missed analyst forecasts. Azenta posted non-GAAP diluted EPS from continuing operations of $0.19, outperforming the $0.14 consensus Non-GAAP EPS estimate. Revenue (GAAP) was $144 million, essentially unchanged from a year earlier and $5.38 million below the $149.38 million GAAP estimate. Margin improvements and cash flow gains came from disciplined cost controls, against a backdrop of challenged sales growth. Management reiterated its full-year FY2025 targets of 3% to 5% organic revenue growth and approximately 300 basis points of adjusted EBITDA Margin expansion, highlighting stable operations but also signaling ongoing pressures in certain business segments.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report.
Azenta operates in the life sciences sector, offering a range of sample management solutions and multiomics services. These include automated storage systems, cryogenic systems, genomic sequencing services, and sample biorepositories tailored for pharmaceutical, biotech, and academic clients worldwide. The company underwent a significant transformation in recent years, moving away from its roots in semiconductor automation and refocusing exclusively on the life sciences market. This shift included divesting its semiconductor business and expanding its portfolio through targeted acquisitions like Barkey Holding, which enhanced its cold chain and bioprocessing storage capabilities.
Source Fool.com
